| 余 萍,刘玲玲,周星利,马金兰,普措卓嘎.视网膜光凝术联合雷珠单抗治疗新生血管青光眼的疗效及对血液流变学和房水炎性因子的影响[J].现代生物医学进展英文版,2021,(19):3787-3791. |
| 视网膜光凝术联合雷珠单抗治疗新生血管青光眼的疗效及对血液流变学和房水炎性因子的影响 |
| Effect of Retinal Photocoagulation Combined with Leizumab in the Treatment of Neovascular Glaucoma and Its Effect on Hemorheology and Inflammatory Factors of Atrial Fluid |
| Received:February 22, 2021 Revised:March 18, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.19.039 |
| 中文关键词: 新生血管青光眼 视网膜光凝术 雷珠单抗 疗效 血液流变学 炎性因子 |
| 英文关键词: Neovascular glaucoma Retinal photocoagulation Leizhumab Efficacy Hemorheology Inflammatory factor |
| 基金项目:青海省科技厅资助项目（2017-ZJ-756）；青海大学中青年科研基金项目（2018-QYY-10） |
|
| Hits: 748 |
| Download times: 419 |
| 中文摘要: |
| 摘要 目的：探讨新生血管青光眼采用视网膜光凝术联合雷珠单抗治疗的疗效及对房水炎性因子和血液流变学的影响。方法：选取我院2015年2月～2017年5月收治的172例（180眼）新生血管青光眼患者作为研究对象，按照随机数字表法分为两组，对照组患者85例（88眼），采用视网膜光凝术进行治疗，观察组患者87例（92眼），采用视网膜光凝术联合雷珠单抗进行治疗，对比两组治疗后虹膜新生血管消退情况及消退时间，治疗前后眼压变化情况和静脉循环时间、眼部光学相干断层扫描（OCT）、血液流变学、房水炎性因子检测结果与不良反应发生情况。结果：观察组虹膜新生血管消失率为95.65%，高于对照组的80.68%（P＜0.05）；与对照组对比，观察组虹膜新生血管消退时间更短（P＜0.05）；与对照组对比，观察组治疗后眼压更低，静脉循环时间更短（P＜0.05）；与对照组对比，观察组治疗后视野缺损值更小，视网膜神经纤维层（RNFL）厚度更厚（P＜0.05）；治疗后观察组血浆黏度(PV)、红细胞压积( HCT)、血小板黏附率(PAdT)水平均低于对照组（P＜0.05）；治疗后观察组房水炎性因子水平包括白介素-1β(IL-1β)、白介素-6(IL-6)、单核细胞趋化蛋白1(MCP-1)水平均低于对照组（P＜0.05）；对照组不良反应发生率为9.09%，与观察组的10.87%对比无统计学差异（P＞0.05）。结论：新生血管青光眼采用视网膜光凝术联合雷珠单抗治疗的疗效理想，可改善患者的血液流变学指标，降低房水炎性因子水平，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of retinal photocoagulation combined with leizumab in the treatment of neovascular glaucoma and its effect on hemorheology and inflammatory factors of atrial fluid. Methods: From February 2015 to May 2017, 172 cases (180 eyes) of neovascularization glaucoma patients were treated in our hospital were selected as the research object. According to random number table method, they were divided into two groups, control group patients with 85 cases (88 eyes), they were used the retinal photocoagulation treatment, observation group of patients with 87 cases (92 eyes), they were used the retinal photocoagulation combined with licensed resistance treatment. After treatment, iris neovascularization regression and regression time, intraocular pressure changes and venous circulation time before and after treatment, eye optical coherence tomography (OCT), hemorheology, aqueous humor inflammatory factors detection results and adverse reactions were compared between the two groups. Results: The rate of iris neovascularization status was 95.65% in the observation group, which was higher than 80.68% in the control group (P<0.05). Compared with the control group, the iris neovascularization regression time in the observation group was shorter(P<0.05). Compared with the control group, the intraocular pressure in the observation group was lower after treatment, the venous circulation time was shorter after treatment (P<0.05). Compared with the control group, the visual field defect value in the observation group after treatment was smaller and the Retinal nerve fiber layer (RNFL) thickness was thicker (P<0.05). After treatment, the levels of plasma viscosity (PV), hematocrit (HCT) and platelet adhesion rate (PAdT) in the observation group were lower than those in the control group (P<0.05); the levels of inflammatory factors in aqueous humor including IL-1 β, IL-6 and MCP-1 in the observation group were lower than those in the control group (P<0.05); The incidence of adverse reactions in the observation group was 10.87%, with no significant difference compared with 9.09% in the control group (P>0.05). Conclusion: Retinal photocoagulation combined with ranibizumab is effective in the treatment of neovascular glaucoma. It can improve the hemorheological indexes, reduce the level of inflammatory factors of atrial fluid, and has high safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
